What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2028, assessing data, trends, opportunities and prospects there.
Our 183-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.
Forecasts from 2018-2028 and other analyses show you commercial prospects
Besides revenue forecasting to 2028, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.
The report also includes will find revenue forecasts to 2028 for the following submarkets in the companion diagnostics market:
• Theranostics
• Other Companion Diagnostics
Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.
The report also includes will find revenue forecasts to 2028 for the following national and regional markets for companion diagnostics:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• India
• Russia
• Brazil
• South Korea
The report provides detailed profiles of key companies operating within the companion diagnostics market:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific
Leading companies and potential for market growth
Overall revenue for the Companion Diagnostics market will reach $14.60n in 2023, our work forecasts. We predict strong revenue growth through to 2028. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2028.
Our work analyses the key companies in the market. See visiongain’s analysis of 7 leading companies, including these:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific
A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships
Discover capabilities, progress, and commercial prospects, helping you stay ahead.
What issues will affect the companion diagnostics industry?
Our new report discusses issues and events affecting the companion diagnostics market. You will find discussions, including qualitative analyses:
• Highly diverse market needing strong knowledge of key therapeutic indications
• Changing regulatory landscape challenging new entrants and major market players alike
• Emerging therapies with the potential to reshape the market
You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.
How the Companion Diagnostics: Market Forecast 2018-2028 report helps you
In summary, our 183-page report gives you the following knowledge:
• Revenue forecasts to 2028 for the Companion Diagnostics market – discover the industry’s prospects, finding promising places for investments and revenues
• Revenue forecasts to 2028 for each major submarket – discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
• Revenue forecasts to 2028 for twelve leading national markets – US, Germany, France, Italy, Spain, UK, Japan, China, India, Russia, Brazil and South Korea
• Assessment of 7 leading companies – analysis of products, revenue, mergers & acquisitions, sales by region and products
• Discussion of what stimulates and restrains companies and the market
• Prospects for established firms and those seeking to enter the market
You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunities. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s study is for everybody needing commercial analyses for the companion diagnostics market and leading companies. You will find data, trends and predictions. Please order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.3 Biomarkers to Companion Diagnostics
2.3.4 Genomic Biomarkers
2.3.5 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA's Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics
3. The World Companion Diagnostics Market, 2017-2028
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2016 and 2017
3.3 The Global Companion Diagnostics Market Sales Forecast, 2017-2028
3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2017
3.7 Theranostics: Fastest Growing Segment of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2017-2028
4. Leading National Markets for Companion Diagnostics, 2017-2028
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2017
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2017-2028
4.2.1 Changing Market Shares of Leading National Markets, 2017-2028
4.3 The US Companion Diagnostics Market Sales Forecast, 2017-2028
4.3.1 The US Will Continue to Dominate the Market
4.4 The EU5 Companion Diagnostics Sales Market, 2017
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2017-2028
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast 2017-2028
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2017-2028
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2017 2028
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2017-2028
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2017-2028
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2017-2028
4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2017-2028
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2017-2028
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2017-2028
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2017-2028
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2017-2028
4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2017-2028
5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 US FDA Approved Companion Diagnostic Tests, 2016
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014
6. Business Models and Stakeholders in the Companion Diagnostics Market
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-Alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Big Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders Influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2017
7. Leading Companies in the Companion Diagnostics Market 2017
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2016
7.1.3 Roche Diagnostics by Region, 2016
7.1.4 Roche: Growing Diagnostic Portfolio
7.1.5 Approval of Ventana and Cobas EGFR Mutation Test V2
7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2017
7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2017
7.1.8.1 Roche/Ariosa Diagnostics and Signature Diagnostics
7.1.8.2 Loxo Oncology/ Roche: Larotrectinib Pan-TRK IHC Companion Diagnostic
7.1.8.3 CAPP Medical/ Roche: Development for Diagnostic Operating Segment
7.1.8.4 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
7.1.8.5 Foundation Medicine/Roche
7.1.8.6 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.8.7 Merck/Ventana: CDx for an Undisclosed Target
7.1.8.8 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.8.9 Boehringer Ingelheim/Roche
7.1.8.10 ImmunoGen/ Ventana
7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2012-2016
7.2.2 Qiagen Sales by Region
7.2.3 Qiagen’s Portfolio of Marketed Companion Diagnostics, 2016
7.2.4 Companion Diagnostics Collaboration Agreements with Pharma, 2016
7.2.4.1 Collaboration with Therawis Diagnostics
7.2.4.2 Collaboration with HTG Molecular Diagnostics
7.2.4.3 Collaboration with Array BioPharma
7.2.4.4 Collaboration with Singulex
7.2.4.5 Strategic Acquisitions
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2014-2016
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Collaborations
7.3.3.1 Collaboration with Celgene and Agios
7.3.3.2 Collaboration with AstraZeneca
7.3.3.3 Collaborative Efforts with Idera
7.4 Agilent Technologies (Dako)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2016
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Approvals
7.4.4.1 Expanded FDA Approval for the Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Gastric or Gastroesophageal Junction (GEJ) Cancer
7.4.4.2 Agilent/ Bristol- Myers Squibb’s: Companion Diagnostic Approvals
7.4.4.3 Agilent/Pfizer/Merck: An Ongoing Collaboration
7.4.5 Strategic Acquisitions
7.4.5.1 Acquisition of i-Lab Solutions
7.4.5.2 Acquisition of Multiplicom
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2016
7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/BeiGene: Collaboration Agreement
7.5.4.2 Myriad/AstraZeneca: Complementary Diagnostic FDA Approvals
7.5.4.3 Acquisition of /Sividone Diagnostics
7.5.4.4 Acquisition of Assurex Health
7.5.4.5 Collaboration with AbbVie
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2016
7.6.2 Sales by Region, 2016
7.6.3 Sales by Technology, 2016
7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.4.1 Strategic Acquisitions
7.6.4.2 Collaboration with Banyan Biomarkers
7.6.4.3 Agreement with Astute Medical to Distribute Nephrocheck
7.6.4.4 Mergers, Acquisitions and Collaborations
7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
7.7 Thermo Fisher Scientific
7.7.1 Sales and Recent Performance Analysis, 2014-2016
7.7.1.1 Thermo Fisher Scientific Sales by Region, 2016
7.7.2 Recent Collaborations and Acquisitions
7.7.2.1 Thermo Fisher Scientific/Seegene-FDA Clearances
7.7.2.2 Thermo Fisher Scientific/University Hospital Basel
7.7.2.3 Acquisition of Alfa Aesar
7.7.2.4 Affymetrix: Thermo Fisher’s Next Target
7.7.2.5 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC
8. Qualitative Analysis of the Companion Diagnostics Market, 2017-2028
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Targeted Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]
9. Conclusions
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks
10. Glossary
Associated Reports
Visiongion Report Sales Order Form
Appendix A
About Visiongain
Appendix B
Visiongain Report Evaluation Form
Table of Tables
Table 1.1 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
Table 1.2 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
Table 2.1 Examples of Clinically Relevant Cancer Biomarkers, 2016
Table 3.1 The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2017
Table 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 3.3 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 3.4 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 3.5 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 3.6 CDx Market Share (%) in the IVD Market, 2017, 2023, 2028
Table 3.7 The World Companion Diagnostics Market: Revenue ($bn) and Market Share (%) by Submarket, 2017
Table 3.8 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2017-2023
Table 3.9 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2023-2028
Table 3.10 Revenue ($bn) and Market Share (%) of Submarkets in the CDx Market, 2017, 2023, 2028
Table 4.1 The Leading National Markets for CDx: Sales ($m), Market Share (%), 2017
Table 4.2 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2017-2023
Table 4.3 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2023-2028
Table 4.4 Revenue ($bn) and Market Share (%) of the National Markets in the CDx Market, 2017, 2023, 2027
Table 4.5 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
Table 4.6 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
Table 4.7 The EU5 CDx Market Forecast: Revenue ($bn) and Market Share (%), 2017
Table 4.8 The EU5 Companion Diagnostic National Market Forecasts: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.9 The EU5 Companion Diagnostic National Market Forecasts: Revenues ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.10 Market Share (%) of Each EU5 Region in the CDx Market, 2017, 2023, 2027
Table 4.11 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 4.12 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Table 4.13 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.14 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.15 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.16 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.17 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.18 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.19 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.20 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.21 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2017-2023
Table 4.22 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2023-2028
Table 4.23 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.24 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.25 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.26 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.27 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.28 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2027-2028
Table 4.29 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.30 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.31 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.32 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 4.33 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2023
Table 4.34 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2023-2028
Table 5.1 List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
Table 5.2 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
Table 5.3 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
Table 5.4 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
Table 5.5 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2018
Table 5.6 List of Cleared or Approved Companion Diagnostic Devices and Their Complementary Therapeutic Drug, 2015-2017
Table 5.7 List of CDx Diagnostic/Pharma Partnerships, 2015-2017
Table 6.1 List of Companies in the Companion Diagnostics Market, 2017
Table 6.2 (Cont’d) List of Companies in the Companion Diagnostics Market, 2017
Table 7.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2016
Table 7.2 Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2016
Table 7.3 Roche: Instruments/devices planned for 2017
Table 7.4 Roche: Tests/Assays planned for 2017
Table 7.5 Roche Diagnostics: List of Marketed Companion Diagnostics, 2017
Table 7.6 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2012-2016
Table 7.7 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2014-2016
Table 7.8 Qiagen: Marketed Molecular Diagnostic Products, 2016
Table 7.9 Qiagen’s Molecular Diagnostics by Therapeutic Area, 2016
Table 7.10 Abbott: Revenue ($bn) by Segment, 2014-2016
Table 7.11 Abbott Molecular: Biomarker Pipeline, 2017
Table 7.12 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016
Table 7.13 Myriad Genetics: Biomarker Product Portfolio, 2016
Table 7.14 Myriad Genetics: Revenue ($bn) by Segment, FY ended June 2015- FY ended June 2017
Table 7.15 bioMérieux : Revenue (€bn), ($bn) and AGR (%), 2012-2016
Table 7.16 bioMérieux: Revenue Share (%) by Technology, 2016
Table 7.17 Thermo Fisher Scientific: Revenue ($bn) and Market Share (%)
Table 7.18 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2016
Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2017-2028
Table 9.1 Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2017, 2023 and 2028
Table of Figures
Figure 1.1 Companion Diagnostics: Overview of Submarkets
Figure 2.1 Development of Biomarkers into Companion Diagnostics, 2018
Figure 3.1 The World IVD Market: Market Share (%) in the IVD Market, 2017
Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Figure 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2023
Figure 3.5 The World CDx Market Share (%) in the IVD Market, 2028
Figure 3.6 The World Companion Diagnostics Market: Market Share (%) by Submarket, 2017
Figure 3.7 The World CDx Market by Submarket: Revenue ($bn) and AGR (%) 2017-2028
Figure 3.8 The World CDx Market Share (%) in the IVD Market, 2023
Figure 3.9 The World CDx Market Share (%) in the IVD Market, 2028
Figure 4.1 The Leading National Markets for CDx by Sales ($bn), 2017
Figure 4.2 The Leading National Markets for CDx by Market Share (%), 2017
Figure 4.3 The Leading National Markets for CDx by Market Share (%), 2023
Figure 4.4 The Leading National Markets for CDx by Market Share (%), 2027
Figure 4.5 The US CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
Figure 4.6 The EU5 Leading National Markets for CDx by Revenue ($bn), 2017
Figure 4.7 The EU5 Leading National Markets for CDx by Market Share (%), 2017
Figure 4.8 The EU5 National Markets for CDx by Market Share (%), 2023
Figure 4.9 The EU5 National Markets for CDx by Market Share (%), 2028
Figure 4.10 The German CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.11 The French CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.12 The Italian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.13 The Spanish CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.14 The UK CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.15 The Japanese CDx Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
Figure 4.16 The Chinese CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.17 The Indian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.18 The Brazilian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.19 The Russian CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.20 The South Korean CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 4.21 The Rest of the World CDx Market Forecast: Revenue ($bn) and AGR (%) 2017-2028
Figure 6.1 Current Business Models for the Development of Companion Diagnostics, 2017
Figure 6.2 Stakeholders in the Companion Diagnostics Market, 2017
Figure 7.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2016
Figure 7.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2016
Figure 7.3 Roche Diagnostics: Revenue Share (%) by Geography, 2016
Figure 7.4 Qiagen: Revenue ($bn) and Net Income ($bn), 2012-2016
Figure 7.5 Qiagen: Revenue Share (%) by Geography, 2016
Figure 7.6 Abbott Laboratories: Historical Revenue ($bn), 2013-2016
Figure 7.7 Abbott Laboratories: Revenue Share (%) by Business Sector, 2016
Figure 7.8 Agilent Technologies: Revenue ($bn) by Business Segment 2014-2016
Figure 7.9 Myriad Genetics: Segment Share (%), 2016
Figure 7.10 bioMérieux: Revenue ($bn) and AGR (%), 2012-2016
Figure 7.11 bioMérieux: Revenue by Region (%), 2016
Figure 7.12 bioMérieux: Revenue Share (%) by Technology, 2015
Figure 7.13 Thermo Fisher Scientific: Revenue Sales (%) by Business Sector, 2016
Figure 7.14 Thermo Fisher Scientific: Revenue Share (%) by Geography, 2016
Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2017-2028
Figure 8.2 Porter’s Five Analysis of the Companion Diagnostics Market, 2017-2028
Figure 9.1 Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2017, 2023 and 2028
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
